Michelle Steinhilb, Ph.D.

About Dr. Steinhilb:

Michelle Steinhilb received her B.S. from Wayne State University in 1996 and received her Ph.D. in biochemistry from the University of Michigan in 2002. Michelle’s graduate studies focused on the cellular trafficking and metabolism of the Alzheimer’s disease Amyloid Precursor Protein (APP) using cell culture models. She continued to study neurodegenerative disease during her postdoctoral studies at Harvard Medical School and Brigham and Women’s Hospital, where she used the fruit fly Drosophila melanogaster as a genetic model system. Her research interests include molecular genetics, cellular and molecular biology, and neurodegeneration.

Publications

• Khurana V, Lu Y, Steinhilb ML, Oldham S, Shulman JM, Feany MB. TOR-mediated cell cycle activation causes neurodegeneration in a Drosophila tauopathy model. Current Biology (2006) Feb 7; 16(3): 230-241.
• King GD, Perez RG, Steinhilb ML, Gaut JR, Turner RS. X11a modulates secretory and endocytic trafficking and metabolism of Amyloid Precursor Protein: Mutational analysis of the YENPTY sequence. Neuroscience (2003) 120(1): 143-154.
• Ho CS, Marinescu V, Steinhilb ML, Gaut JR, Turner RS, Stuenkel EL. Synergistic effects of Munc18a and X11 proteins on Amyloid Precursor Protein metabolism. J. Biol. Chem. (2002) Jul 26; 277(30): 27021-27028.
• Steinhilb ML, Turner RS, Gaut JR. ELISA Analysis of beta-secretase cleavage of the swedish Amyloid Precursor Protein in the secretory and endocytic pathways. J. Neurochem. (2002) Mar; 80(6):1019-1028.
• Gau JT, Steinhilb ML, Kao TC, D’Amato CJ, Gaut JR, Frey KA, Turner RS. Stable beta-secretase activity and presynaptic cholinergic markers during progressive central nervous system amyloidogenesis in Tg2576 mice. Am. J. Pathol. (2002) 160(2): 731-738.
• Steinhilb ML, Turner RS, and Gaut JR. The protease inhibitor, MG132, blocks maturation of the Amyloid Precursor Protein Swedish mutant preventing cleavage by beta-Secretase. J. Biol. Chem. (2001) Feb 9; 276(6): 4476-4484.